Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema

BACKGROUND: Diabetic macular edema (DME) can be treated with different alternatives, among them Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) has demonstrated that may improve both central macular thickness (CMT) and best corrected visual acuity (BCVA). This study aimed to evaluate the effect...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Ophthalmol
Auteurs principaux: Castro-Navarro, Verónica, Cervera-Taulet, Enrique, Navarro-Palop, Catalina, Monferrer-Adsuara, Clara, Hernández-Bel, Laura, Montero-Hernández, Javier
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6330395/
https://ncbi.nlm.nih.gov/pubmed/30634940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12886-018-1022-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires